Good Choice of pALliative Chemotherapy to Patient With Pancreatic Cancer ; GemcitAbine Therapy vs FOLFORINOX therapY

Launched by BORYUNG PHARMACEUTICAL CO., LTD · Mar 7, 2021

Keywords

ClinConnect Summary

This clinical trial is investigating the best types of chemotherapy for patients with locally advanced or metastatic pancreatic cancer, which means the cancer has spread beyond the pancreas. Specifically, it compares two treatment options: Gemcitabine therapy and FOLFIRINOX therapy. The goal is to understand how these treatments are used in real-life settings in Korea and to learn why doctors choose one treatment over the other.

To participate in the study, you need to be an adult aged 19 or older and have a confirmed diagnosis of locally advanced or metastatic pancreatic cancer. You also need to be planning to receive palliative chemotherapy, which aims to relieve symptoms and improve quality of life rather than cure the cancer. If you decide to join, you will be fully informed about the study and will need to sign a consent form allowing the use of your personal information. This trial is currently recruiting participants, and it’s important to note that certain individuals, such as those with other cancers or those who are pregnant, may not be eligible.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients are briefed about the study objectives and methodologies, and express their consent by signing a written agreement for the use of their personal information.
• • 2. Male and female adults who are ≥ 19 years old at the time of enrollment.
• • 3. Locally advanced or metastatic pancreatic cancer patients whose diagnosis was confirmed histologically or cytologically.
• • 4. Patients who plan to receive palliative chemotherapy (e.g., FOLFIRINOX, Gemcitabine-based therapy, etc.)
• Exclusion Criteria:
• • 1. Patients who are diagnosed with any other primary cancer that may influence pancreatic cancer treatment or prognosis.
• • 2. Patients who are currently or have a history of receiving palliative chemotherapy.
• • 3. Female patients who are pregnant, have childbearing potential or are breastfeeding.
• • 4. Patients who are currently participating in other clinical trials (clinical trials for drugs or medical devices) or are planning to participate in other clinical trials during the study period. However, patients participating in a non-interventional observational study or registry study can be enrolled.
• • 5. Other patients who are judged by the investigator to be ineligible to participate in the study.